S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN Price Target & Analyst Ratings

$95.07
0.00 (0.00%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$94.14
$95.43
50-Day Range
$71.48
$96.00
52-Week Range
$70.73
$97.76
Volume
910,317 shs
Average Volume
1.24 million shs
Market Capitalization
$17.63 billion
P/E Ratio
365.67
Dividend Yield
N/A
Price Target
$110.93

BioMarin Pharmaceutical Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 15 Analyst Ratings

Consensus Analyst Price Target

$110.93
16.69% Upside
High Prediction$135.00
Average Prediction$110.93
Low Prediction$70.00
TypeCurrent
8/13/21 to 8/13/22
1 Month Ago
7/14/21 to 7/14/22
3 Months Ago
5/15/21 to 5/15/22
1 Year Ago
8/13/20 to 8/13/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
7 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$110.93$108.57$114.31$111.04
Predicted Upside16.69% Upside27.11% Upside32.63% Upside30.84% Upside
Get BioMarin Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.


BMRN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BMRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioMarin Pharmaceutical Stock vs. The Competition

TypeBioMarin PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.71
2.50
Consensus RatingModerate BuyBuyHold
Predicted Upside16.69% Upside723.73% Upside13.81% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1496
76.25%
Underperform Votes
466
23.75%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/9/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$111.00+14.75%
8/9/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$125.00 ➝ $128.00+33.75%
8/4/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$113.00 ➝ $117.00+25.25%
8/4/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$115.00 ➝ $122.00+38.01%
8/4/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$112.00 ➝ $125.00+41.40%
7/12/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$110.00+25.21%
6/28/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$112.00+31.63%
6/24/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andreas Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$70.00-19.40%
5/4/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$100.00+19.73%
5/3/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$96.00+15.23%
1/10/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$125.00 ➝ $135.00+54.30%
11/22/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$84.00 ➝ $95.00+4.00%
11/22/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Debjit Chattopadhyay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$103.00 ➝ $120.00+30.46%
11/22/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$129.00 ➝ $135.00+46.77%
11/22/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
9/7/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kennen MacKay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$88.00+12.17%
3/1/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$90.00 ➝ $100.00+29.15%
8/19/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$148.00 ➝ $86.00-27.45%
8/14/2020The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$172.00 ➝ $218.00+82.14%
8/6/2020BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$94.00 ➝ $108.00-9.28%
6/18/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$109.00 ➝ $143.00+24.39%
6/10/2020Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$120.00 ➝ $130.00+23.70%
5/10/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$115.00+20.80%
4/30/2020Nomura
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$77.00-18.38%
3/2/2020Nomura Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Marai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$77.00-18.43%
1/2/2020Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
12/16/2019Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$150.00+80.81%
9/13/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetBuy$120.00+65.18%
(Data available from 8/13/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BMRN Price Target - Frequently Asked Questions

What is BioMarin Pharmaceutical's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for BioMarin Pharmaceutical stock is Moderate Buy based on the current 3 hold ratings and 12 buy ratings for BMRN. The average twelve-month price prediction for BioMarin Pharmaceutical is $110.93 with a high price target of $135.00 and a low price target of $70.00. Learn more on BMRN's analyst rating history.

Do Wall Street analysts like BioMarin Pharmaceutical more than its competitors?

Analysts like BioMarin Pharmaceutical more than other Medical companies. The consensus rating for BioMarin Pharmaceutical is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how BMRN compares to other companies.

Do MarketBeat users like BioMarin Pharmaceutical more than its competitors?

MarketBeat users like BioMarin Pharmaceutical more than other Medical companies. 76.25% of MarketBeat users gave BioMarin Pharmaceutical an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does BioMarin Pharmaceutical's stock price have much upside?

According to analysts, BioMarin Pharmaceutical's stock has a predicted upside of 25.95% based on their 12-month price targets.

What analysts cover BioMarin Pharmaceutical?

BioMarin Pharmaceutical has been rated by Barclays, Cantor Fitzgerald, Credit Suisse Group, Morgan Stanley, Piper Sandler, Robert W. Baird, SVB Leerink, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:BMRN) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.